In the original [] and in our earlier publication [], the control sample of beta-2-microglobulin amyloids before their treatment with active substances (trypsin and alpha-B-crystalline) was the same. Therefore, the micrographs at time zero (Figure 5A in [] and Figure 1 in []) partially overlap. The reference [] is the reference [34] of  the publication []. And the new reference citation  to the caption of Figure 5A of the publication [] and information about this overlapping has now been inserted.
The citation has now been inserted in Figure 5 caption and should read:
“(A) The electron micrographs of amyloid fibrils in the absence (Partly Reprinted from ref. [34]) and at different time points after the addition of trypsin to the samples.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
References
- Stepanenko, O.V.; Sulatsky, M.I.; Mikhailova, E.V.; Stepanenko, O.V.; Kuznetsova, I.M.; Turoverov, K.K.; Sulatskaya, A.I. Trypsin Induced Degradation of Amyloid Fibrils. Int. J. Mol. Sci. 2021, 22, 4828. [Google Scholar] [CrossRef] [PubMed]
 - Stepanenko, O.V.; Sulatsky, M.I.; Mikhailova, E.V.; Stepanenko, O.V.; Povarova, O.I.; Kuznetsova, I.M.; Turoverov, K.K.; Sulatskaya, A.I. Alpha-B-Crystallin Effect on Mature Amyloid Fibrils: Different Degradation Mechanisms and Changes in Cytotoxicity. Int. J. Mol. Sci. 2020, 21, 7659. [Google Scholar] [CrossRef] [PubMed]
 
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.  | 
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).